Comprehensive Echocardiographic and Speckle Tracking Strain Analysis in Rheumatic Mitral Stenosis Patients before and after Transvenous Mitral Commissurotomy

Aslannif Bin Roslan (elysess1@gmail.com)  
Institut Jantung Negara

Faten A Aris  
IJN: INSTITUT JANTUNG NEGARA

Tey Yee Sin  
IJN: INSTITUT JANTUNG NEGARA

Afif Ashari  
IJN: INSTITUT JANTUNG NEGARA

Abdul A Shaparudin  
IJN: INSTITUT JANTUNG NEGARA

Wan Faizal W Rahimi Shah  
IJN: INSTITUT JANTUNG NEGARA

Lee Tjen Jhung  
IJN: INSTITUT JANTUNG NEGARA

Koh Hui Beng  
IJN: INSTITUT JANTUNG NEGARA

Ahmad Tantawi Jauhari Aktifanus  
IJN: INSTITUT JANTUNG NEGARA

Amin Ariff Nuruddin  
INSTITUT JANTUNG NEGARA

Research Article

Keywords: Echocardiography, rheumatic mitral valve, mitral stenosis, strain

Posted Date: November 9th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-1041308/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Version of Record: A version of this preprint was published at The International Journal of Cardiovascular Imaging on January 3rd, 2022. See the published version at https://doi.org/10.1007/s10554-021-02518-3.
Abstract

Purpose

Percutaneous Transvenous Mitral Commissurotomy (PTMC) is the first line treatment for rheumatic mitral stenosis (MS). We sought to evaluate 1) changes in 2-dimensional (2D) echocardiographic and strain values and 2) differences in these values for patients in atrial fibrillation (AF) and sinus rhythm (SR) pre, immediately and 6 months post PTMC.

Methods

Retrospective study of 136 patients who underwent PTMC between 2011 and 2021. We analyzed their 2D echocardiogram, Global Longitudinal Strain (GLS), Left Atrial Reservoir Strain (LAr-S) and Right Ventricle Free Wall Strain (RVFW-S) pre, immediately and 6 months post PTMC.

Results

At 6 months, mitral valve area increases from 0.94 ± 0.23 cm\(^2\) to 1.50 ± 0.42 cm\(^2\). Ejection fraction (EF) did not change post PTMC (pre; 55.56 ± 6.62%, immediate; 56.68 ± 7.83%, 6 months; 56.28 ± 7.00%, p=0.218). Even though EF is preserved, GLS is lower pre-procedure; -11.52 ± 3.74% with significant improvement at 6 months; -15.16 ± 4.28% (p<0.001). Tricuspid annular plane systolic excursion (TAPSE) improved at 6 months from 1.95 ± 0.43 to 2.11 ± 0.49 (p=0.004). RVFW-S increases at 6 months from -17.37 ± 6.03% to -19.75 ± 7.19% (p<0.001). LAr-S improved from 11.23 ± 6.83% pre PTMC to 16.80 ± 8.82% at 6 months (p<0.001) post PTMC. Pre-procedure patients with AF have lower strain values (More LV, RV and LA dysfunction) with statistically significant difference for LAr-S (p < 0.001), GLS (p <0.001) and RVFW-S (p <0.001) than patients in SR.

Conclusion

Patients with severe rheumatic MS have subclinical left and right ventricle dysfunction despite preserved EF and relatively normal TAPSE with significant improvement seen at 6 months post PTMC. AF patients have lower baseline strain values than SR patients.

Introduction

Percutaneous Transvenous Mitral Commissurotomy (PTMC) is an established treatment for severe rheumatic mitral stenosis (MS) since its first publication in 1984 [1]. The aim is to crack the fused commissures thereby increasing the mitral valve area and reducing the mean pressure gradient (mean PG) across the mitral valve [2, 3]. Prior studies have shown that the left ventricle (LV) ejection fraction (EF) is preserved in MS and the EF also does not change significantly immediately post PTMC [2–4]. Speckle tracking strain allows us to look at subclinical left ventricle (LV) and right ventricle (RV) dysfunction by analyzing Global Longitudinal Strain (GLS), Right Ventricle Free Wall Strain (RVFW-S) and left atrial dysfunction by looking at Left Atrial Reservoir Strain (LAr-S) [5–8]. With regards to subclinical
LV and RV dysfunction, there are prior studies showing reduction in Global Longitudinal Strain (GLS) and Right Ventricle Free Wall Strain (RVFW-S), but the study population is small, and these studies only analyzed pre and immediate post PTMC values [7–14]. To our knowledge, this is the first study that tracks all aspects of strain (GLS, RVFW-S and LAr-S) pre, immediately and 6 months post procedure. Atrial fibrillation (AF) commonly coexists with MS and there is no study thus far looking at baseline strain values and response to PTMC in this group of patients compared to those in sinus rhythm (SR) [15–16].

**Materials And Methods**

We looked at medical records of all patients who underwent PTMC at our center from 2011 to 2021. All patients included had mitral valve area < 1.5cm². We excluded patients with more than mild mitral regurgitation and those whose echocardiographic images were deemed not suitable for strain analysis. This study has been approved by our institution ethics committee.

**Echocardiographic data**

All the patients’ echocardiographic images were analyzed using the Synapse Cardiovascular software. We analyzed the images looking at 8 echocardiographic parameters. To evaluate the left heart, we measured biplane Simpson EF and left atrial volume index (LAVI), and to evaluate the mitral valve we measured mitral valve area by planimetry (MVA) in short axis view, and mitral valve area by pressure half time (MVA PHT) in apical 4 chamber view. In patients with atrial fibrillation (AF) we averaged 3 cardiac cycles to acquire measurements. For the right heart, we measured systolic pulmonary artery pressure (s-PAP), calculated from maximum tricuspid regurgitation velocity (TR Vmax) and inferior vena cava (IVC) size and collapsibility 5mm distal to hepatic vein insertion, tricuspid annular plane systolic excursion (TAPSE) and right ventricle fractional area change (FAC).

**Strain analysis**

Only patients with suitable apical 4 chamber (A4C), apical 2 chamber (A2C) and apical 3 chamber (A3C) views were included in the study. The strain was analyzed retrospectively using Tom-Tec software. We analyze global longitudinal strain (GLS), right ventricle free wall strain (RVFW-S) and left atrial reservoir strain (LAr-S). Echocardiography and strain analysis was performed for all enrolled patients pre-PTMC (within one-month pre-procedure), immediately post-procedure (one day post-procedure) and 6 months after the procedure. This is the standard echocardiographic follow up protocol for PTMC patients in our setting (Figure 1a,1b and Figure 2a,2b).

**Statistical analysis**

Numerical measurements were expressed as mean ± standard deviation, whereas categorical data expressed as frequency and proportion. A repeated measures ANOVA was used to compare differences between groups at different times points with a Grehouse-Geisser correction and post hoc analysis of
Bonferroni correction where applicable. P values < 0.05 were considered statistically significant. Statistical analysis was performed using SPSS ver. 27.0 (SPSS, Chicago, IL, USA).

Results

Overall, there were 136 patients with severe rheumatic MS who underwent PTMC during a 10-year period between 2011 to 2021 at our center. There were 113 (83.10%) female and 23 (16.90%) male patients. All these patients had no or mild MR. Overall age of intervention was 45.05 ± 13.34 years old (female; 45.42 ± 13.77 years old, male; 43.29 ± 11.03 years old). The mean Wilkins score was 6.60 ± 1.61. 82 (60.29%) patients had SR, and 54 (39.71%) patients had AF pre-PTMC. At the time of writing, all these patients are still alive with 16 (11.76%) of them underwent re-intervention. (Table 1)

Table 1
Demographics and Wilkins Score

|                  | Overall     | Female      | Male        |
|------------------|-------------|-------------|-------------|
| n (%             | 136 (100.00%) | 113 (83.10%) | 23 (16.90%) |
| Age (Mean ± SD)  | 45.05 ± 13.34 | 45.42 ± 13.77 | 43.29 ± 11.03 |
| Wilkins Score (Mean ± SD) | 6.60 ± 1.61 | 6.58 ± 1.63 | 6.70 ± 1.58 |

Analysing the 2D echocardiographic parameters, MVA by planimetry increased from 0.94 ± 0.23cm² to 1.45 ± 0.38cm² post PTMC (p < 0.001) and to 1.50 ± 0.42cm² at 6 months (p < 0.001). The mean PG went down from 10.79 ± 4.42mmHg pre to 5.26 ± 1.97mmHg post (p<0.001) and 6.21 ± 2.53 at 6 months (p<0.001) while the s-PAP went down from 46.61 ± 21.80mmHg pre to 34.98 ± 14.46mmHg post and 35.12 ± 12.45mmHg at 6 months post PTMC (overall p<0.001). With regards to left heart parameters, the EF was preserved pre-PTMC and there were no statistically significant changes post PTMC or at 6 months (Pre; 55.56 ± 6.62% post; 56.68 ± 7.83% 6 months; 56.28 ± 7.00%, Overall p=0.218). LAVI decreased from 82.05 ± 32.76mls/m² pre to 73.12 ± 28.47mls/m² post (p=0.001) and 76.41 ± 33.17mls/m² (p=0.110) at 6 months post procedure. For the right side of the heart, TAPSE did not improve immediately post PTMC but showed improvement at 6 months. [Pre; 1.95 ± 0.43, post; 1.93 ± 0.48 (p=1.00) 6 months; 2.11 ± 0.49 (p = 0.004)]. Conversely FAC improved immediately post PTMC 35 ± 11% to 40 ± 9% (p<0.001) but saw no significant gain at 6 months [39 ± 10%, p=0.947 (post vs 6 months)]. (Table 2)
### Table 2
Traditional Echocardiographic Parameters for All Patients Pre, Immediate and 6 months post PTMC

| Characteristics | Pre       | Post Immediate | Post 6 months | Overall p value | p value post-hoc analysis |
|-----------------|-----------|----------------|---------------|----------------|----------------------------|
|                 |           |                |               |                | Pre-to-post | Post-to-6 month | Pre-to 6-month |
| MVA Planimetry  | 0.94 ± 0.23 | 1.45 ± 0.38   | 1.50 ± 0.42   | <0.001         | <0.001        | 0.627          | <0.001         |
| MVA PHT         | 0.97 ± 0.25 | 1.49 ± 0.40   | 1.50 ± 0.42   | <0.001         | <0.001        | 1.000          | <0.001         |
| Mean PG         | 10.79 ± 4.42 | 5.26 ± 1.97   | 6.21 ± 2.53   | <0.001         | <0.001        | <0.001         | <0.001         |
| s-PAP           | 46.61 ± 21.80 | 34.98 ± 14.46 | 35.12 ± 12.45 | <0.001         | <0.001        | 1.000          | <0.001         |
| RV TAPSE        | 1.95 ± 0.43  | 1.93 ± 0.48   | 2.11 ± 0.49   | <0.001         | 1.000         | 0.001          | 0.004          |
| EF              | 55.56 ± 6.62 | 56.68 ± 7.83  | 56.28 ± 7.00  | 0.218          |               |                |                |
| LAVI            | 82.05 ± 32.76 | 73.12 ± 28.47 | 76.41 ± 33.17 | 0.001          | 0.001         | 0.410          | 0.110          |
| RV FAC          | 0.35 ± 0.11  | 0.40 ± 0.09   | 0.39 ± 0.10   | <0.001         | <0.001        | 0.947          | 0.006          |

Analyzing the speckle tracking strain analysis data, it is of interest to note that while EF and TAPSE were normal prior to PTMC, there were significant subclinical left ventricle and right ventricle dysfunction. GLS was markedly depressed pre PTMC; -11.52 ± 3.74% with no improvement immediately post PTMC; -12.19 ± 5.64% (p=0.632). There were, however, significant improvement at 6 months; -15.2 ± 4.3% (p<0.001) (31.60% improvement). RVFW-S pre PTMC was also depressed at -17.37 ± 6.03%. Like GLS and TAPSE it did not improve immediately post-PTMC; -17.34 ± 7.32% (p=1.000) but improved significantly at 6 months; -19.75 ± 7.19% (p=0.011). Overall improvement in RVFW-S was 13.70%. Finally, LAr-S was the only strain parameter with significant immediate and 6 months improvement post-PTMC (Pre; 11.23 ± 6.83% to Post; 13.50 ± 7.83% (p=0.011) 6 months; 16.80 ± 8.82% (p<0.001) with overall improvement of 49.60%. (Table 3, Figure 3)
Table 3
Speckle Tracking Analysis, LA reservoir, LA Conduit, LA Booster, GLS and RVFWS for All Patients Pre, Post Immediate and 6 months post PTMC

| Speckle Tracking | Pre       | Post Immediate | Post 6 months | Overall p value | p value post-hoc analysis |
|-----------------|-----------|----------------|---------------|-----------------|---------------------------|
|                 |           |                |               | Pre-to-post     | Post-to-6 month           | Pre-to 6-month       |
| LAr-S           | 11.23 ± 6.83 | 13.50 ± 7.83   | 16.80 ± 8.82  | <0.001          | 0.011                     | <0.001               |
| LAc-S           | 6.58 ± 4.42  | 9.12 ± 4.99    | 10.41 ± 4.76  | <0.001          | <0.001                    | 0.061                | <0.001               |
| LA booster      | 8.08 ± 4.05  | 7.65 ± 4.47    | 11.42 ± 5.33  | <0.001          | 1.000                     | <0.001               | 0.002                |
| GLS             | -11.52 ± 3.74 | -12.19 ± 5.64  | -15.16 ± 4.28 | <0.001          | 0.632                     | <0.001               | <0.001               |
| RVFW-S          | -17.37 ± 6.03 | -17.34 ± 7.32  | -19.75 ± 7.19 | 0.003           | 1.000                     | 0.005                | 0.011                |

In terms of traditional echocardiographic parameters, patients with AF had lower TAPSE and lower FAC at all measured points pre and post PTMC compared to patients in SR (TAPSE p<0.001 and FAC p=0.010). AF patients had lower strain values (More LV, RV and LA dysfunction) with statistically significant difference for LAr-S (p < 0.001), GLS (p <0.001) and RVFW-S (p <0.001) compared to patients in SR. Pre PTMC GLS for AF vs SR; (-9.56 ± 3.34% vs -12.86 ± 3.42%), pre RVFWS AF vs SR; (-14.46 ± 5.40% vs -19.37 ± 5.65) and pre-LAr-S AF vs SR (7.58 ± 5.30% vs 13.84 ± 6.63%).

In AF patients, GLS increased from -9.56 ± 3.34% pre PTMC to -13.24 ± 3.91% at 6 months (p<0.001 Absolute improvement= 38.49%) compared to -12.86 ± 3.42% to -16.48 ± 4.04% at 6 months (p<0.001 Absolute improvement=28.15%) for SR patients. Amongst patients with AF, the LAr-S improved from 7.58 ± 5.30% to 10.66 ± 5.03% (p = 0.028 Absolute improvement= 40.63%), whereas for patients in SR, it improved from 13.84 ± 6.63% to 21.18 ± 8.34% (p<0.001 Absolute improvement= 53.03%). For RVFW-S, AF patients saw numerical improvement -14.46 ± 5.40% to -16.38 ± 5.52% at 6 months (p = 0.232 Absolute improvement=13.28%) and for SR patients it improved from -19.37 ± 5.65% to 22.07 ± 7.33% at 6 months (p = 0.065 Absolute improvement=13.94%). However, for RVFW-S these changes failed to reach statistical significance (Table 4, Table 5, and Figure 4).
Table 4
Echocardiographic and strain analysis for patients with atrial fibrillation vs patients with sinus rhythm

| Characteristics | Sinus Rhythm | Atrial Fibrillation | p value |
|-----------------|--------------|----------------------|---------|
| s-PAP           |              |                      |         |
| Pre             | 46.50 ± 19.53| 46.72 ± 24.21        | 0.222   |
| Post immediate  | 34.07 ± 14.00| 35.92 ± 15.07        |         |
| Post 6 months   | 30.63 ± 9.05 | 39.73 ± 13.85        |         |
| RV TAPSE        |              |                      |         |
| Pre             | 2.18 ± 0.31  | 1.58 ± 0.33          | <0.001  |
| Post immediate  | 2.16 ± 0.39  | 1.56 ± 0.34          |         |
| Post 6 months   | 2.34 ± 0.44  | 1.75 ± 0.30          |         |
| RV FAC          |              |                      |         |
| Pre             | 0.36 ± 0.11  | 0.33 ± 0.11          | 0.010   |
| Post immediate  | 0.41 ± 0.08  | 0.39 ± 0.09          |         |
| Post 6 months   | 0.40 ± 0.10  | 0.37 ± 0.10          |         |
| LAr-S           |              |                      |         |
| Pre             | 13.84 ± 6.63 | 7.58 ± 5.30          | <0.001  |
| Post immediate  | 16.44 ± 8.14 | 9.38 ± 5.11          |         |
| Post 6 months   | 21.18 ± 8.34 | 10.66 ± 5.03         |         |
| LAc-S           |              |                      |         |
| Pre             | 5.87 ± 3.54  | 7.58 ± 5.30          | 0.732   |
| Post immediate  | 9.26 ± 5.23  | 8.93 ± 4.71          |         |
| Post 6 months   | 10.68 ± 5.13 | 10.04 ± 4.21         |         |
| GLS             |              |                      |         |
| Pre             | -12.86 ± 3.42| -9.56 ± 3.34         | <0.001  |
| Post immediate  | -14.14 ± 3.84| -9.35 ± 6.61         |         |
| Post 6 months   | -16.48 ± 4.04| -13.24 ± 3.91        |         |
| RVFW-S          |              |                      |         |
| Pre             | -19.37 ± 5.65| -14.46 ± 5.40        | <0.001  |
| Characteristics | Sinus Rhythm | Atrial Fibrillation | p value |
|-----------------|--------------|---------------------|---------|
| Post immediate  | -19.49 ± 7.52| -14.22 ± 5.83       |         |
| Post 6 months   | -22.07 ± 7.33| -16.38 ± 5.52       |         |

Table 5
Overall changes, Changes for AF vs SR patients

| Speckle Tracking | Pre    | Post Immediate | Post 6 months | % Difference | p value¹ | p value² | p value³ |
|------------------|--------|----------------|---------------|--------------|----------|----------|----------|
| LAr-S            |        |                |               |              |          |          |          |
| Overall          | 11.23 ± 6.83 | 13.50 ± 7.83 | 16.80 ± 8.82 | 49.60%       | <0.001   |          |          |
| Sinus Rhythm     | 13.84 ± 6.63 | 16.44 ± 8.14 | 21.18 ± 8.34 | 53.03%       | <0.001   | <0.001   | 0.020    |
| Atrial Fibrillation | 7.58 ± 5.30 | 9.38 ± 5.11 | 10.66 ± 5.03 | 40.63%       | 0.028    |          |          |
| GLS              |        |                |               |              |          |          |          |
| Overall          | -11.52 ± 3.74 | -12.19 ± 5.64 | -15.16 ± 4.28 | 31.60%       | <0.001   |          |          |
| Sinus Rhythm     | -12.86 ± 3.42 | -14.14 ± 3.84 | -16.48 ± 4.04 | 28.15%       | <0.001   | <0.001   | 0.211    |
| Atrial Fibrillation | -9.56 ± 3.34 | -9.35 ± 6.61 | -13.24 ± 3.91 | 38.49%       | <0.001   |          |          |
| RVFW-S           |        |                |               |              |          |          |          |
| Overall          | -17.37 ± 6.03 | -17.34 ± 7.32 | -19.75 ± 7.19 | 13.70%       | 0.011    |          |          |
| Sinus Rhythm     | -19.37 ± 5.65 | -19.49 ± 7.52 | -22.07 ± 7.33 | 13.94%       | 0.065    | <0.001   | 0.889    |
| Atrial Fibrillation | -14.46 ± 5.40 | -14.22 ± 5.83 | -16.38 ± 5.52 | 13.28%       | 0.232    |          |          |

* p values¹ suggested any statistically significance of value differences at % difference pre to post 6 months

* p values² suggested any statistically significance of value differences between groups regardless different time points

* p values³ suggested any statistically significance of possible interaction of value differences between groups and different time points
Finally, we evaluated whether there were any significant differences between patients who underwent reintervention (n=16) vs those who did not (n=120). The only significant difference was those who needed intervention had lower EF at all measured timepoints compared to those without re-intervention (p=0.015). There was no difference in GLS, RVFW-S and LAr-S between the 2 groups. (Table 6).
| Characteristics | No Re-intervention | Re-intervention | p value |
|-----------------|-------------------|----------------|---------|
| MVA Planimetry  |                   |                |         |
| Pre             | 0.92 ± 0.21       | 1.14 ± 0.24    | 0.386   |
| Post immediate  | 1.45 ± 0.39       | 1.44 ± 0.20    |         |
| Post 6 months   | 1.50 ± 0.41       | 1.50 ± 0.51    |         |
| MVA PHT         |                   |                |         |
| Pre             | 0.96 ± 0.25       | 0.99 ± 0.25    | 0.259   |
| Post immediate  | 1.49 ± 0.40       | 1.49 ± 0.42    |         |
| Post 6 months   | 1.48 ± 0.36       | 1.70 ± 0.71    |         |
| Mean PG         |                   |                |         |
| Pre             | 10.86 ± 4.43      | 10.33 ± 4.56   | 0.722   |
| Post immediate  | 5.19 ± 1.91       | 5.76 ± 2.41    |         |
| Post 6 months   | 6.13 ± 2.50       | 6.85 ± 2.78    |         |
| s-PAP           |                   |                |         |
| Pre             | 45.75 ± 21.16     | 53.40 ± 26.96  | 0.513   |
| Post immediate  | 34.75 ± 14.76     | 36.78 ± 12.56  |         |
| Post 6 months   | 35.14 ± 11.39     | 34.95 ± 20.04  |         |
| RV TAPSE        |                   |                |         |
| Pre             | 1.93 ± 0.43       | 2.07 ± 0.46    | 0.766   |
| Post immediate  | 1.93 ± 0.48       | 1.92 ± 0.48    |         |
| Post 6 months   | 2.11 ± 0.48       | 2.09 ± 0.53    |         |
| EF              |                   |                |         |
| Pre             | 56.06 ± 6.59      | 51.92 ± 5.87   | 0.015   |
| Post immediate  | 57.37 ± 7.37      | 51.58 ± 9.53   |         |
| Post 6 months   | 56.71 ± 6.99      | 53.08 ± 6.40   |         |
| LAr-S           |                   |                |         |
| Pre             | 11.27 ± 6.90      | 10.95 ± 6.58   | 0.966   |
## Discussion

The standard first line treatment for severe rheumatic MS is PTMC which has been done all over the world since the first publication of its’ success in 1984 on 5 patients [1]. The aim of PTMC is to relief the obstruction across the mitral valve by cracking open the fused commissures, hence the name “commissurotomy” [1]. There are many studies showing significant increases in MVA and reduction in mean PG post PTMC [1–3]. PTMC is generally associated with good outcomes with low procedural and long-term mortality, but with significant need for re-intervention in the future. [17–19]

In term of left ventricular function, there is a notion that MS protects the LV, thus systolic function should be preserved [13]. Many studies have shown that the EF is indeed preserved pre and immediately post PTMC [2–4]. Our study further confirms this fact and additionally demonstrates this phenomenon even at 6 months. Strain is a relatively new method to evaluate LV, RV and LA dysfunction before these become apparent using traditional 2D- echocardiographic parameters [20]. The basic principle of strain echocardiography is recognition of 2 points on the myocardium and evaluation of how much these points move away or towards each other during pre-specified periods of the cardiac cycle. This value is expressed as a percentage [20, 21]. For GLS, the normal value is more negative than -18%, for RVFW-S normal value is more negative than -25% and for LAr-S normal value is more than 45% [22, 23]. Initial doppler tissue-based strain showed significant subclinical LV dysfunction in patients with severe MS [5]. With the advent of speckle tracking strain, analysis is easier, with greater reproducibility and not angle dependent [22]. Utilization of speckle tracking strain in previous studies also demonstrated significant reduction in GLS amongst severe MS patients with preserved EF [6–9], with one study demonstrating a relationship between MS progression and GLS [14]. Our study is unique because we track the changes in

| Characteristics | No Re-intervention | Re-intervention | p value |
|-----------------|--------------------|----------------|---------|
| Post immediate  | 13.46 ± 7.70       | 13.76 ± 9.01   |         |
| Post 6 months   | 16.76 ± 8.71       | 17.04 ± 9.99   |         |
| GLS             |                    |                |         |
| Pre             | -11.68 ± 3.74      | -10.37 ± 3.67  | 0.886   |
| Post immediate  | -12.11 ± 5.71      | -12.75 ± 5.32  |         |
| Post 6 months   | -15.14 ± 4.26      | -15.33 ± 4.61  |         |
| RVFW-S          |                    |                |         |
| Pre             | -17.26 ± 5.91      | -18.08 ± 7.03  | 0.590   |
| Post immediate  | -17.30 ± 7.47      | -17.55 ± 6.56  |         |
| Post 6 months   | -19.54 ± 6.93      | -21.15 ± 8.99  |         |
GLS pre, immediately and 6 months post PTMC and found that while GLS did not improve immediately, there was significant improvement 6 months post PTMC with overall improvement of 31.6%.

As a result of the hemodynamic sequelae and back pressure from the obstructed mitral valve, patients with severe rheumatic MS commonly have increase in s-PAP [2, 3]. Despite this, many studies have shown that the TAPSE is still above the cut-off for abnormal values based on the American Society of Echocardiography guidelines (Abnormal TAPSE < 1.7) [22, 23]. In our study the TAPSE pre-PTMC is 1.9 ± 0.4 with no improvement immediately but significantly improve at 6 months (Table 2). With regards to strain, prior to our publication there is a study that showed improvement in RVFS-S immediately post PTMC [8]. Like that study, we also found that RVFW-S was significantly depressed pre-PTMC, and as with GLS and TAPSE there were no immediate improvements, but RVFW-S improved significantly at 6 months post-PTMC.

Patients with severe MS all have left atrial dilatation, and many are at risk of developing atrial fibrillation [15]. In our study the LAr-S was markedly depressed but unlike GLS and RVFW-S, LAr-S improved immediately and continued to improve at 6 months post procedure. The 6 months period required for significant improvement in GLS, and RVFW-S seems to suggest that post PTMC, there is progressive positive remodelling of LV, RV, and left atrium.

This study also shows the importance of early intervention before AF develops. All strain parameters are lower for AF patients compared to those in sinus rhythm. Regardless of the rhythm at intervention, both groups of patients had significant improvement in their strain values post PTMC. Finally, there are 16 patients that required re-intervention (4 re-do PTMC and 12 mitral valves replacement). We are unable to find any statistically different strain parameters, except that those who required re-intervention had significantly lower EF.

**Conclusions**

Severe Rheumatic MS patients have significant impairment in left ventricle, right ventricle and left atrial function as illustrated by low GLS, RVFW-S and LAr-S. PTMC results in significant improvements in all strain parameters at 6 months post procedure. Patients with AF have significantly reduced strain parameters compared to patients in SR, however they still derive significant improvement from PTMC.

**Declarations**

**Fundings**

There are no fundings involved in this study

**Conflict of interests**

The authors declare that they have no conflict of interest
References

1. Inoue K, Owaki T, Nakamura T, Kitamura F, Miyamoto N. Clinical application of transvenous mitral commissurotomy by a new balloon catheter. J Thorac Cardiovasc Surg. 1984 Mar;87(3):394–402.

2. Khan I, Shah B, Habeel Dar M, Khan A, Faisal Iftekhar M, Sami A. Clinical and Echocardiographic Follow-up after Successful Percutaneous Transvenous Mitral Commissurotomy. Cureus. 2017 Sep;9(9):e1726.

3. Khan A, Shafiq I, Jan M, Hassan Z. Echocardiographic assessment before and after Percutaneous Transvenous Mitral Commissurotomy in patients with Rheumatic Mitral Stenosis. Pakistan J Med Sci. 2021;37(1):104–8.

4. Gaasch WH, Folland ED. Left ventricular function in rheumatic mitral stenosis. Eur Heart J [Internet]. 1991 Jul 1;12(suppl_B):66–9. Available from: https://doi.org/10.1093/eurheartj/12.suppl_B.66

5. Dogan S, Aydin M, Gursurer M, Dursun A, Onuk T, Madak H. Prediction of subclinical left ventricular dysfunction with strain rate imaging in patients with mild to moderate rheumatic mitral stenosis. J Am Soc Echocardiogr. 2006 Mar;19(3):243–8.

6. Ozdemir AO, Kaya CT, Ozcan OU, Ozdol C, Candemir B, Turhan S, et al. Prediction of subclinical left ventricular dysfunction with longitudinal two-dimensional strain and strain rate imaging in patients with mitral stenosis. Int J Cardiovasc Imaging [Internet]. 2010;26(4):397–404. Available from: https://doi.org/10.1007/s10554-009-9550-2

7. Simşek Z, Karakelleoğlu S, Gündoğdu F, Aksakal E, Sevimli S, Arslan S, et al. Evaluation of left ventricular function with strain/strain rate imaging in patients with rheumatic mitral stenosis. Anadolu Kardiyol Derg. 2010 Aug;10(4):328–33.

8. Khanna R, Raghuvanshi AS, Kumar S, Garg N, Tewari S, Kapoor A, et al. Immediate impact of percutaneous transvenous mitral commissurotomy on right ventricle longitudinal strain in patients of mitral stenosis. Echocardiography [Internet]. 2018 Oct 1;35(10):1525–32. Available from: https://doi.org/10.1111/echo.14093

9. Bilen E, Kurt M, Tanboga IH, Kaya A, Isik T, Ekinci M, et al. Severity of mitral stenosis and left ventricular mechanics: a speckle tracking study. Cardiology. 2011;119(2):108–15.

10. Caso P, Ancona R, Di salvo G, Pinto S, Macrino M, Palma V, et al. Atrial reservoir function by strain rate imaging in asymptomatic mitral stenosis: Prognostic value at 3 year follow-up. Eur J Echocardiogr. 2009 Jun 1;10:753–9.

11. Ancona R, Comenale Pinto S, Caso P, Di Salvo G, Severino S, D'Andrea A, et al. Two-dimensional atrial systolic strain imaging predicts atrial fibrillation at 4-year follow-up in asymptomatic rheumatic mitral stenosis. J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr. 2013 Mar;26(3):270–7.
12.  Rohani A, Kargar S, Fazlinejad A, Ghaderi F, Vakili V, Falsoleiman H, et al. Acute effect of treatment of mitral stenosis on left atrium function. Ann Card Anaesth. 2017;20(1):42–4.

13.  Sravan K Reddy N, Ranjan Shetty K, Sudhakar Rao M, Sree Madhurya Reddy M. Strain imaging to assess early effects of successful percutaneous balloon mitral valvotomy on left atrium mechanics. Egypt Hear J [Internet]. 2019;71(1):25. Available from: https://doi.org/10.1186/s43044-019-0021-3

14.  Gerede DM, Ongun A, Kaya CT, Acibucu A, Özyüncü N, Erol Ç. Use of strain and strain rate echocardiographic imaging to predict the progression of mitral stenosis: A 5-year follow-up study. Anatol J Cardiol. 2016;16(10):772–7.

15.  Pourafkari L, Ghaffari S, Bancroft GR, Tajlil A, Nader ND. Factors associated with atrial fibrillation in rheumatic mitral stenosis. Asian Cardiovasc Thorac Ann. 2015 Jan;23(1):17–23.

16.  Westermann D, Schrage B. Mitral stenosis and atrial fibrillation. Vol. 106, Heart (British Cardiac Society). 2020. p. 713.

17.  Fazir O Al, Amin A, Robaayah Z, Ali RM. TCT-808 15-year Outcomes and Predictors of Success for Percutaneous Mitral Commissurotomy for Rheumatic Mitral Stenosis. J Am Coll Cardiol [Internet]. 2014 Sep 16;64(11_Supplement):B236–B236. Available from: https://doi.org/10.1016/j.jacc.2014.07.883

18.  Murthy Jayanthi Sriram SN, Venkata BJ, Sadagopan T, Ramamurthy MT. Immediate, intermediate and long term clinical outcomes of percutaneous transvenous mitral commissurotomy. IJC Hear Vasc [Internet]. 2015;6:66–70. Available from: https://www.sciencedirect.com/science/article/pii/S235290671500007X

19.  Kim D, Chung H, Nam JH, Park DH, Shim CY, Kim JS, et al. Predictors of long-term outcomes of percutaneous mitral valvuloplasty in patients with rheumatic mitral stenosis. Yonsei Med J. 2018;59(2):273–8.

20.  Mondillo S, Galderisi M, Mele D, Cameli M, Lomoriello VS, Zacà V, et al. Speckle-tracking echocardiography: a new technique for assessing myocardial function. J ultrasound Med Off J Am Inst Ultrasound Med. 2011 Jan;30(1):71–83.

21.  Bansal M, Kasliwal RR. How do i do it? Speckle-tracking echocardiography. Indian Heart J [Internet]. 2013;65(1):117–23. Available from: http://dx.doi.org/10.1016/j.ihj.2012.12.004

22.  Badano LP, Kolas TJ, Muraru D, Abraham TP, Aurigemma G, Edvardsen T, et al. Standardization of left atrial, right ventricular, and right atrial deformation imaging using two-dimensional speckle tracking echocardiography: a consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. Eur Hear journal Cardiovasc Imaging. 2018 Jun;19(6):591–600.

23.  Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of
Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14.

Figures

Figure 1
Example of a patient pre and post strain analysis for left atrial reservoir (Lar-S) and right ventricle free wall (RVFW-S) strain. 1a and 1b Pre-PTMC LA-r S (Figure 1a) of 10.5% improved to 16.4% at 6 months post PTMC (Figure 1b)

![Figure 1a and 1b Pre-PTMC LA-r S](image1a.png)

RVFWSL: -12.9 %
RV4CSL: -12.6 %

![Figure 2a and 2b Pre-PTMC RVFW S](image2a.png)

RVFWSL: -14.1 %
RV4CSL: -13.1 %

**Figure 2**

2a and 2b Pre-PTMC RVFW S (Figure 2a) of -12.9% improved to -14.1% at 6 months post PTMC (Figure 2b)
Figure 3

Strain analysis pre, immediately post and 6 months after PTMC. Immediately post procedure, only Left Atrial Reservoir (LAr-S) have statistically significant improvement. However, at 6-months post procedures all 3 strain types improves significantly.

Figure 4
Strain for patients with AF vs patient in SR Pre-PTMC patients with Atrial Fibrillation (AF) have lower Global Longitudinal Strain (GLS), Right Ventricle Free Wall Strain (RVFW-S) and Left Atrial Reservoir Strain (LAr-S) than patient in Sinus Rhythm (SR) but still derive significant benefit from PTMC